Novartis has escaped a false advertising charge in Japan tied to questionable data on its heart drug Diovan. It was one of a series of missteps for the Swiss…

Get ready to negotiate, payers: Amgen has its PCSK9 outcomes data. In a long-awaited trial, Repatha cut heart attack risks by 27% and stroke risks by 21%. Will…

AstraZeneca’s Lynparza honed its edge in ovarian cancer on Tuesday, just in time to help preserve its lead in the marketplace.

Investors who wanted GSK to sink its CEO-designate Emma Walmsley's base salary may not be happy with her just-announced compensation package.

​​​​​​​Merck & Co. could have a growing Zostavax problem. Several plaintiffs have sued, claiming the shingles vaccine caused serious injury and death, more…

Sen. Bernie Sanders lays into TV network execs for their “lack of coverage” on drug pricing.

Plenty of companies have talked about—and even dabbled in—newfangled pricing schemes. But Novartis is about to seriously raise the bar with new cancer-fighter…

Mylan and partner Biocon cleared another hurdle with their version of Roche’s breast cancer med Herceptin, one of the biggest biosim targets in the market.

AbbVie’s Richard Gonzalez was already on the list of highest-paid biopharma CEOs for 2015. And in 2016, his total pay rose even higher.

Corporate